Grünenthal Developed Novel Resiniferatoxin for the Treatment of Knee Osteoarthritis
Grünenthal developed novel resiniferatoxin (RTX), for the pain associated with osteoarthritis (OA) of the knee which is currently undergoing clinical Phase III development.
Resiniferatoxin, is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. By administering it as an intra-articular injection directly into the knee joint, it aims to defunctionalise TRPV1-expressing nociceptors, providing long-lasting pain relief for patients with knee osteoarthritis. Preliminary data showed a significant analgesic effect and functional improvement compared to placebo with a favourable safety profile.
Millions of patients suffering from knee osteoarthritis eagerly await additional treatment options, as the disease currently lacks a cure. Resiniferatoxin holds promise as a potential solution to alleviate the pain associated with this condition.
Resiniferatoxin, if granted approval, holds promising potential as a non-opioid treatment option that can offer enduring pain relief and enhance the functioning of the affected joint. Additionally, it demonstrates a favourable safety profile, further adding to its value as a viable treatment alternative.
U.S. Food and Drug Administration (FDA) grants breakthrough designation for resiniferatoxin for the treatment of pain associated with knee osteoarthritis.
